Hubble Therapeutics desarrollará una cura de terapia génica para LCA16

– Hubble Therapeutics cierra una ronda de financiación de Serie A para desarrollar una cura de terapia génica para LCA16 HANOVER, N.H., 25 de marzo de 2025 /PRNewswire/ — Hubble Therapeutics LLC, una empresa de biotecnología centrada en el paciente que desarrolla una terapia genética…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.